Latest 8-K filings

Albany International announced robust second-quarter 2026 financial results, showcasing significant increases in net income and Adjusted EBITDA, driven by strong performance in its Engineered Composites segment.

Thryv Holdings reported a net loss and declining revenue in Q2 2026, alongside a strategic restructuring plan aimed at improving operating efficiencies and focusing on its SaaS platform.

Zeo ScientifiX announces the launch of ZEO Xperience, a three-day educational event for healthcare professionals focused on regenerative biologics.

Palvella Therapeutics announced strong Q2 2026 financial results, highlighting significant progress in its QTORIN rapamycin NDA submission for microcystic lymphatic malformations and advancement of other pipeline programs.

NRG Energy announced robust second quarter 2026 financial results, highlighted by significant year-over-year increases in GAAP Net Income and Adjusted EBITDA, while reaffirming its full-year financial guidance.

Westlake Corporation announced a substantial improvement in its second quarter 2026 financial results, driven by enhanced net income, EBITDA, and strategic operational improvements.

Westlake Chemical Partners LP announced second quarter 2026 results, reporting $14.2 million in net income and a significant increase in operating cash flow, while declaring its 48th consecutive quarterly distribution.

Angel Oak Mortgage REIT announced its second quarter 2026 financial results, reporting $3.4 million in GAAP net income and $9.0 million in distributable earnings, while also detailing strategic portfolio actions.

Theriva Biologics, Inc. announced that its stockholders approved amendments to the 2020 Stock Incentive Plan and an increase in authorized shares at the 2026 Annual Meeting.

TransDigm Group announced robust third quarter fiscal 2026 results, including a 23% increase in net sales and a 10% rise in net income, leading to an upward revision of its full-year financial guidance.

TOP Financial Group Limited announces a significant strategic expansion to establish a dedicated Artificial Intelligence division and integrate advanced AI solutions across its core financial business operations.

Barnwell Industries announces the sale of its remaining Hawaii development interests for $1.77 million, a move aimed at portfolio simplification and strengthening its balance sheet.

Xometry Inc. announced record second quarter 2026 results, with revenue soaring 41% year-over-year to $229 million, driven by a 45% surge in marketplace revenue and improved Adjusted EBITDA.

Shoals Technologies Group reported a significant 47.4% revenue increase in Q2 2026 to $163.4 million, driven by strong demand and market share capture, while Adjusted EBITDA also rose, though gross profit margins declined due to operational inefficiencies and product quality costs.

IREN Limited announced the successful closing of its acquisition of Mirantis, Inc., significantly enhancing its AI Cloud platform with Mirantis' software expertise and customer base.

Strata Critical Medical announced a 60.7% year-over-year revenue increase to $72.5 million in Q2 2026, driven by acquisitions and organic growth, alongside improved Adjusted EBITDA and positive operating cash flow.

Superior Group of Companies announced its second quarter 2026 financial results, reporting an increase in total net sales and a rise in adjusted EBITDA, while also confirming its full-year outlook.

CAMP4 Therapeutics announced the second closing of its private placement, raising approximately $50.1 million to advance its CMP-002 program for SYNGAP1-related disorder.

Certara announced its second quarter 2026 financial results, reporting modest revenue growth, a net loss, and a decrease in Adjusted EBITDA, while reaffirming its full-year revenue guidance and authorizing an additional $50 million share repurchase program.

AdaptHealth Corp. announced its second quarter 2026 financial results, reporting a net loss and lowering its full-year outlook, while also detailing the divestiture of its Diabetes Health business.

Beam Therapeutics announced second quarter 2026 financial results, highlighting progress in its AATD, PKU, and SCD programs, with a strong cash runway extending into mid-2029.

TELA Bio, Inc. announces the immediate departure of CEO Antony Koblish and the appointment of Heather Getz as the new Chief Executive Officer and a director.

Enpro Inc. reported a strong second quarter of 2026 with a 17.6% year-over-year sales increase and raised its full-year financial guidance.

iBio, Inc. announced the appointment of Dr. Molly Carr as its new Chief Medical Officer, a move aimed at bolstering its clinical strategy and advancing its pipeline.

Elite Pharmaceuticals announces the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP) in multiple strengths.

RYTHM, Inc. announced a robust second quarter for 2026, with revenue soaring 73% sequentially to $23.0 million, alongside a net income of $1.2 million and improved Adjusted EBITDA of $6.4 million.

Katapult Holdings announced second quarter 2026 results, showing a 4.7% increase in gross originations and a 4.0% rise in revenue, while significantly improving Adjusted EBITDA and reducing net loss, as the company progresses towards its merger with The Aarons Company and CCF Holdings.

Wayfair Inc. announced robust second quarter 2026 financial results, showcasing a 7.5% year-over-year net revenue increase and the strongest free cash flow generation since the second quarter of 2020.

Larimar Therapeutics reported strong Q2 2026 results, highlighting progress in its rolling BLA submission for nomlabofusp and positive long-term study data for Friedreich's Ataxia.

Pfizer reported robust second-quarter 2026 financial results, driven by strong performance in launched and acquired products, leading to an upward revision of its full-year revenue guidance.